Systemic Lupus Erythematosus (SLE)
Conditions
Interventions
belimumab group:Low-dose cyclophosphamide combined with belimumab
cyclophosphamide group:Standard dose cyclophosphamide
Sponsors
The Second Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. SLE patients admitted to the Second Hospital of Shanxi Medical University from January 2021 to June 2022; 2. All patients eligible participants are >=18 years old and meet the diagnostic criteria for systemic lupus erythematosus by the American College of Rheumatology or the systemic lupus erythematosus international cooperative clinic for systemic lupus erythematosus criteria; 3. Seropositive antinuclear antibodies (ANAs) and/or anti-double-stranded DNA (anti-dsDNA) antibody screening are required; 4. Some people have active serious disease. Defined as having a British Isles Lupus Assessment (BILAG) organ system score of >=1 (severe disease activity) or having a BILAGB score (moderate disease activity); 5. From April 2014 to June 2016, a total of 42 patients who received conventional treatment were included as historical controls.
Exclusion criteria
Exclusion criteria: 1. Coexistence of another autoimmune disease; 2. Any known intolerance or contraindication to CTX and other DMARDs, acute infection, cancer or other malignant disease, other connective tissue disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BILAG; | — |
Countries
China
Contacts
Public ContactWen Hongyan
The Second Hospital of Shanxi Medical University
Outcome results
None listed